CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2 monoclonal antibody (AB011), as monotherapy and combination therapy, for patients with advanced solid tumors was presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), in San Francisco, California, during January 19-21, 2023.

Details for the presentation are as follows:

Poster Presentation: A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-CLDN18.2 Monoclonal Antibody, as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors (Abstract #391, Poster #G13)

Presenter: Jin Li MD

Session Title: Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers